La/SSB chimeric autoantibody receptor modified NK92MI cells for targeted therapy of autoimmune disease
- 1 July 2018
- journal article
- research article
- Published by Elsevier in Clinical Immunology
- Vol. 192, 40-49
Abstract
No abstract availableKeywords
Funding Information
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- National Natural Science Foundation of China (31471283)
- Collaborative Innovation Major Project (XYXT2015304)
- Six Talent Peaks Project (SWYY-CXTD-010)
This publication has 41 references indexed in Scilit:
- Arming NK cells with enhanced antitumor activityOncoImmunology, 2013
- The Tumor Lysis SyndromeNew England Journal of Medicine, 2011
- Interleukin-17-producing T cells in lupusCurrent Opinion in Rheumatology, 2010
- Rituximab versus Cyclophosphamide for ANCA-Associated VasculitisNew England Journal of Medicine, 2010
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicityBlood, 2010
- A retrospective seven‐year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college london hospital: The first fifty patientsArthritis Care & Research, 2009
- B‐lymphocyte contributions to human autoimmune diseaseImmunological Reviews, 2008
- Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeksArthritis & Rheumatism, 2006
- Immunotherapy of Malignant Melanoma in a SCID Mouse Model Using the Highly Cytotoxic Natural Killer Cell Line NK-92Journal of Hematotherapy, 1999
- Characterization of Genetically Altered, Interleukin 2-Independent Natural Killer Cell Lines Suitable for Adoptive Cellular ImmunotherapyHuman Gene Therapy, 1999